LUMC Global has set out to stimulate international connections in (bio)medical research and education to contribute to global healthcare. Setting up several PhD projects has been one of the key elements in doing this and we’re very proud we’ve been able to set up as many as eight different PhD projects. We are now looking for a Global PhD candidate in Obstetrics in a collaborative projects with Karolinska Institutet, Sweden and UZ Leuven, Belgium.
What you’ll do
Monochorionic diamniotic twin pregnancies, sharing one placenta with blood vessel anastomosis have a high risk of pregnancy complications. Selective fetal growth restriction (sFGR) occurs when there is unequal placenta sharing. A small placenta shares results in abnormal blood flows and less growth. The growth restricted fetus is at risk for fetal demise, and because of the anastomosis between the twins the other twin is at risk too for fetal demise or severe neurodevelopmental damage. The pathogenesis, diagnostic criteria, management, and outcome of sFGR are not well-established yet.
With this unique collaboration between the LUMC, UZ Leuven, and Karolinska we aim for an important milestone in the research on sFGR. This is where you come in! You will design, execute, and coordinate the collection of data, which you will then process, analyze and interpret. You conduct literature reviews, and give written and oral reports on the outcomes of your research.
The African-European Tuberculosis Consortium (AE-TBC) is an international multisite group of African and European researchers who investigate the use of host biosignatures for the diagnosis of active TB disease. For over ten years, the LUMC groups of Infectious Diseases and Cell & Chemical Biology from Prof Annemieke Geluk and Dr Paul Corstjens respectively, have been partners of the EDCTP consortia for tuberculosis (among which AE-TBC). The AE-TBC recently won the prize for ‘Outstanding Research Team 2020, awarded by the EDCTP.
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
“This is an achievement in alignment with the mission of VODAN-Africa to generate continuous, real-time, high velocity clinical observational patient data from resource-limited communities that have not been well represented in digital health data. The key feature is that the data produced remains in the health facility only. It will not leave the health facility. Since the data is machine-actionable the input of the data only happens once; in the deployable architecture, the data is used for four parallel use cases” (VODAN to Africa, 2022).